Current perspectives on circulating tumor DNA, precision medicine, and personalized clinical management of Cancer

Kelly C.S. Oliveira; Iago Barroso Ramos; Jessica M.C. Silva; Williams Fernandes Barra; Gregory J. Riggins; Vikrant PalanD.E.; Catarina Torres Pinho; Milana Frenkel-Morgenstern; Sidney E.B. Santos; Paulo P. Assumpcao; Rommel R. Burbano; Danielle Queiroz Calcagno

doi:10.1158/1541-7786.mcr-19-0768

Current perspectives on circulating tumor DNA, precision medicine, and personalized clinical management of Cancer

Kelly C.S. Oliveira
, Iago Barroso Ramos
, Jessica M.C. Silva
, Williams Fernandes Barra
, Gregory J. Riggins
, Vikrant PalanD.E.
, Catarina Torres Pinho
, Milana Frenkel-Morgenstern
, Sidney E.B. Santos
, Paulo P. Assumpcao
, Rommel R. Burbano
, Danielle Queiroz Calcagno

Bar-Ilan University - Azrieli Faculty of Medicine

Research output: Contribution to journal › Review article › peer-review

87 Scopus citations

Abstract

Circulating tumor DNA (ctDNA) has recently emerged as a minimally invasive "liquid biopsy" tool in precision medicine. ctDNA-genomic DNA fragments that are released into the bloodstream after the active secretion of microvesicles or tumor cell lysis reflects tumor evolution and the genomic alterations present in primary and/or metastatic tumors. Notably, ctDNA analysis might allow the stratification of patients, the monitoring of the therapeutic response, and the establishment of an opportunity for early intervention independent of detection by imaging modalities or clinical symptoms. As oncology moves towards precision medicine, the information in ctDNA provides a means for the individual management of the patient based on their tumor's genetic profile. This review presents current evidence on the potential role for ctDNA in helping to guide individualized clinical treatment decisions for patients with melanoma, castration-resistant prostate cancer, breast cancer, metastatic colorectal cancer, and non small cell lung cancer.

Original language	English
Pages (from-to)	517-528
Number of pages	12
Journal	Molecular Cancer Research
Volume	18
Issue number	4
DOIs	https://doi.org/10.1158/1541-7786.mcr-19-0768
State	Published - 1 Apr 2020

Bibliographical note

Publisher Copyright:
© 2020 American Association for Cancer Research.

Funding

MCTI Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; to Danielle Q. Calcagno1, 311342/2017-5). The authors are grateful to Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) for all financial support. As well to the organizers and speakers of the “Liquid Biopsies” course

Funders
Conselho Nacional de Desenvolvimento Científico e Tecnológico

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1158/1541-7786.mcr-19-0768

Cite this

Oliveira, K. C. S., Ramos, I. B., Silva, J. M. C., Barra, W. F., Riggins, G. J., PalanD.E., V., Pinho, C. T., Frenkel-Morgenstern, M., Santos, S. E. B., Assumpcao, P. P., Burbano, R. R., & Calcagno, D. Q. (2020). Current perspectives on circulating tumor DNA, precision medicine, and personalized clinical management of Cancer. Molecular Cancer Research, 18(4), 517-528. https://doi.org/10.1158/1541-7786.mcr-19-0768

@article{81a40c5335104cf494c6494de424157d,

title = "Current perspectives on circulating tumor DNA, precision medicine, and personalized clinical management of Cancer",

abstract = "Circulating tumor DNA (ctDNA) has recently emerged as a minimally invasive {"}liquid biopsy{"} tool in precision medicine. ctDNA-genomic DNA fragments that are released into the bloodstream after the active secretion of microvesicles or tumor cell lysis reflects tumor evolution and the genomic alterations present in primary and/or metastatic tumors. Notably, ctDNA analysis might allow the stratification of patients, the monitoring of the therapeutic response, and the establishment of an opportunity for early intervention independent of detection by imaging modalities or clinical symptoms. As oncology moves towards precision medicine, the information in ctDNA provides a means for the individual management of the patient based on their tumor's genetic profile. This review presents current evidence on the potential role for ctDNA in helping to guide individualized clinical treatment decisions for patients with melanoma, castration-resistant prostate cancer, breast cancer, metastatic colorectal cancer, and non small cell lung cancer.",

author = "Oliveira, \{Kelly C.S.\} and Ramos, \{Iago Barroso\} and Silva, \{Jessica M.C.\} and Barra, \{Williams Fernandes\} and Riggins, \{Gregory J.\} and Vikrant PalanD.E. and Pinho, \{Catarina Torres\} and Milana Frenkel-Morgenstern and Santos, \{Sidney E.B.\} and Assumpcao, \{Paulo P.\} and Burbano, \{Rommel R.\} and Calcagno, \{Danielle Queiroz\}",

note = "Publisher Copyright: {\textcopyright} 2020 American Association for Cancer Research.",

year = "2020",

month = apr,

day = "1",

doi = "10.1158/1541-7786.mcr-19-0768",

language = "אנגלית",

volume = "18",

pages = "517--528",

journal = "Molecular Cancer Research",

issn = "1541-7786",

publisher = "American Association for Cancer Research Inc.",

number = "4",

}

Oliveira, KCS, Ramos, IB, Silva, JMC, Barra, WF, Riggins, GJ, PalanD.E., V, Pinho, CT, Frenkel-Morgenstern, M, Santos, SEB, Assumpcao, PP, Burbano, RR & Calcagno, DQ 2020, 'Current perspectives on circulating tumor DNA, precision medicine, and personalized clinical management of Cancer', Molecular Cancer Research, vol. 18, no. 4, pp. 517-528. https://doi.org/10.1158/1541-7786.mcr-19-0768

TY - JOUR

T1 - Current perspectives on circulating tumor DNA, precision medicine, and personalized clinical management of Cancer

AU - Oliveira, Kelly C.S.

AU - Ramos, Iago Barroso

AU - Silva, Jessica M.C.

AU - Barra, Williams Fernandes

AU - Riggins, Gregory J.

AU - PalanD.E., Vikrant

AU - Pinho, Catarina Torres

AU - Frenkel-Morgenstern, Milana

AU - Santos, Sidney E.B.

AU - Assumpcao, Paulo P.

AU - Burbano, Rommel R.

AU - Calcagno, Danielle Queiroz

PY - 2020/4/1

Y1 - 2020/4/1

N2 - Circulating tumor DNA (ctDNA) has recently emerged as a minimally invasive "liquid biopsy" tool in precision medicine. ctDNA-genomic DNA fragments that are released into the bloodstream after the active secretion of microvesicles or tumor cell lysis reflects tumor evolution and the genomic alterations present in primary and/or metastatic tumors. Notably, ctDNA analysis might allow the stratification of patients, the monitoring of the therapeutic response, and the establishment of an opportunity for early intervention independent of detection by imaging modalities or clinical symptoms. As oncology moves towards precision medicine, the information in ctDNA provides a means for the individual management of the patient based on their tumor's genetic profile. This review presents current evidence on the potential role for ctDNA in helping to guide individualized clinical treatment decisions for patients with melanoma, castration-resistant prostate cancer, breast cancer, metastatic colorectal cancer, and non small cell lung cancer.

AB - Circulating tumor DNA (ctDNA) has recently emerged as a minimally invasive "liquid biopsy" tool in precision medicine. ctDNA-genomic DNA fragments that are released into the bloodstream after the active secretion of microvesicles or tumor cell lysis reflects tumor evolution and the genomic alterations present in primary and/or metastatic tumors. Notably, ctDNA analysis might allow the stratification of patients, the monitoring of the therapeutic response, and the establishment of an opportunity for early intervention independent of detection by imaging modalities or clinical symptoms. As oncology moves towards precision medicine, the information in ctDNA provides a means for the individual management of the patient based on their tumor's genetic profile. This review presents current evidence on the potential role for ctDNA in helping to guide individualized clinical treatment decisions for patients with melanoma, castration-resistant prostate cancer, breast cancer, metastatic colorectal cancer, and non small cell lung cancer.

UR - https://www.scopus.com/pages/publications/85082923131

U2 - 10.1158/1541-7786.mcr-19-0768

DO - 10.1158/1541-7786.mcr-19-0768

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.systematicreview???

C2 - 31996469

AN - SCOPUS:85082923131

SN - 1541-7786

VL - 18

SP - 517

EP - 528

JO - Molecular Cancer Research

JF - Molecular Cancer Research

IS - 4

ER -

Current perspectives on circulating tumor DNA, precision medicine, and personalized clinical management of Cancer

Abstract

Bibliographical note

Funding

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this